Alkermes (ALKS) is down about 3% in Friday trading, with the day’s pressure tied to incremental analyst caution rather than a new clinical or regulatory headline. This week, RBC Capital lowered its price target on ALKS to $44 from $45 while maintaining its rating, a modest but notable reset that can weigh on sentiment when the stock is already trading in a choppy tape. (streetinsider.com)

The company is in the middle of a strategic transition toward sleep disorders following its Avadel transaction, which has refocused investor attention on execution risk, timelines, and the durability of growth in the combined portfolio. With the story shifting from legacy franchises to a new commercial and pipeline narrative, even small changes in analyst framing can amplify day-to-day moves as investors recalibrate valuation and expectations. (investing.com)

Near-term focus is likely to remain on 2026 outlook delivery and integration progress, plus any forthcoming updates on the orexin program (including Phase 3 initiation timing) and commercialization trajectory in sleep medicine. Investors will also watch for additional target or estimate changes from other firms, and for company commentary around 2026 revenue expectations and key milestones. (longbridge.com)